Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maculosin is a naturally occurring cyclic dipeptide composed of L-proline and L‑tyrosine. It belongs to the class of pyrazine derivatives and alpha amino acid derivatives. Maculosin has been identified as a secondary metabolite in certain microorganisms and plants. Its mechanism of action is not fully characterized; however, it has been reported to exhibit biological activities such as phytotoxicity and antimicrobial effects in experimental settings. There are no approved therapeutic indications or clinical uses for maculosin at this time[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maculosin.